Insmed Incorporated is a biopharmaceutical company that develops treatments for rare and serious diseases, with its lead approved product treating a rare lung infection caused by nontuberculous mycobacteria in patients with certain underlying lung conditions. The company has focused its research and commercial efforts on conditions with small patient populations and limited existing treatment options, a strategy common among biotechnology companies pursuing rare disease drugs that can command premium pricing given the lack of alternatives. Insmed's pipeline includes additional drug candidates targeting other rare pulmonary and inflammatory conditions, reflecting an effort to expand beyond its initial approved product into a broader portfolio of rare disease treatments. As a biopharmaceutical company, Insmed's results depend heavily on both the commercial performance of its approved treatment and its ability to advance additional pipeline candidates through clinical trials and regulatory approval.